Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Evaluation of Florbetapir F 18
NCT01518374Phase 2Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Dec 2009
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Florbetapir in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegenerative diseases, sponsored by Avid Radiopharmaceuticals. Primary endpoint: Treatment-emergent Adverse Events at 48 hours. Started Dec 2009; status: completed.
02
Drugs
Florbetapir
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)neurodegenerative diseases
Beyond the preview
Go deeper on NCT01518374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01518374.